AML cells have been shown to express the Wilms’ tumor 1 (WT1) protein and upregulation of this protein is a predictor of poor prognosis in AML and MDS patients (Bergmann et al., 1997; Brayer et al., 2015). This evidence concerns the gene WT1 and myelodysplastic syndrome.